1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Ovarian Cancer Recurrent: new trials by email Literature Review of Ovarian Cancer Recurrent trials Research Report on Ovarian Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer Pegylated liposomal doxorubicin plus adebrelimab with mirabegron, Pegylated liposomal doxorubicin plus adebrelimab - Ovarian Cancer Recurrent | Phase 2 / Phase 3 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 296 | 2025-03-18 | 2025-03-18 |
liposomal doxorubicin (1) · mirabegron (1)
Obstetrics & Gynecology Hospital of Fudan University (1)
China (1)